glp 1 and perimenopause Microdosing GLP-1 for Perimenopause: Why Lower Doses Might Be Better THE PCCA BLOG | Managing

While this side effect may not be a dea-lbreaker for those taking the drug to aid their weight-loss journey, its not ideal

CagriSema achieved 22.7% at 68 weeks while tirzepatide achieved 22.5% at 72 weeks

Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress

Mitochondrial dysfunction ( m -Dys)/altered bioenergetics The mitochondrion is the cellular powerhouse involved in oxidative phosphorylation (OXPHOS), ATP synthesis, and regulation of calcium (Ca 2+ ) signaling, redox homeostasis, lipid metabolism, cell differentiation, immune system, apoptosis, and cellular senescence (aging) 155,156

Retatrutide remains in clinical development as of 2026 and is not yet FDA-approved